Elicio Therapeutics Inc.
Last updated September 27, 2026
Organization details
- Legal name
- Elicio Therapeutics Inc.
- Ownership
- Public
- Status
- Active
- Headquarters country
- United States
- Ticker symbol
- ELTX
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001601485
Board of directors
-
Allen Nissenson · DirectorSince 2023
-
Assaf Segal · DirectorSince 2023
-
Carol Gail Ashe · DirectorSince 2023
-
Jay Venkatesan · DirectorSince 2023
-
Julian Adams · DirectorSince 2023
-
Karen J. Wilson · DirectorSince 2023
-
Robert Connelly · Director · CEO, President and DirectorSince 2023
-
Robert R. Ruffolo · DirectorSince 2023
-
Yekaterina Chudnovsky · DirectorSince 2023
Chief executives
Robert Connelly
· CEO, President and Director
Since June 2023
Board connections
5 of this board's directors also sit on 5 other boards.
- via Jay Venkatesan and Karen J. Wilson
- via Karen J. Wilson
- via Yekaterina Chudnovsky
- via Robert R. Ruffolo
- via Allen Nissenson
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $0
- 0 purchases by 0 insiders
- Sold, last 12 months
- $0
- 0 sales by 0 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Feb 2, 2026 | Robert Connelly Director, Officer (CEO, President and Director) | Grant or award | +73,600 | — | — |
| Feb 2, 2026 | Shah Preetam Officer (See Remarks) | Grant or award | +24,000 | — | — |
| Feb 2, 2026 | DeMuth Peter Officer (Chief Scientific Officer) | Grant or award | +20,800 | — | — |
| Feb 2, 2026 | Haqq Christopher Officer (See Remarks) | Grant or award | +25,400 | — | — |
| Dec 9, 2025 | DeMuth Peter Officer (Chief Scientific Officer) | Option exercise | +362 | $4.41 | $1,596 |
| Mar 5, 2025 | Yekaterina Chudnovsky Director, 10% owner | Derivative conversion | +3,500,573 | $5.81 | $20,338,329 |
| Dec 16, 2024 | DeMuth Peter Officer (Chief Scientific Officer) | Option exercise | +381 | $4.41 | $1,680 |
| Nov 26, 2024 | Jay Venkatesan Director | In-the-money exercise | +50,000 | $0.01 | $500 |
| Dec 22, 2023 | Yekaterina Chudnovsky Director, 10% owner | Open-market purchase | +1,213,000 | $5.81 | $7,047,530 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.